

RESEARCH ARTICLE

Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review

Fanny Depont^{1*}, Francis Berenbaum², Jérôme Filippi³, Michel Le Maitre⁴, Henri Nataf⁵, Carle Paul⁶, Laurent Peyrin-Biroulet⁷, Emmanuel Thibout⁸

1 SC Partners, Paris, France, **2** Sorbonne University, UPMC Université Paris 06, UMRS 938, DHU i2B, Department of Rheumatology, AP-HP, Saint-Antoine Hospital, Paris, France, **3** Department of Gastroenterology, Archet 2 Hospital, Nice, France, **4** 60 rue du Tour de Ville, 14880 Colleville-Montgomery, France, **5** François Quesnay Hospital, Mantes la Jolie, France, **6** Department of Dermatology, Paul Sabatier University, Toulouse, France, **7** Inserm U954 and Department of Gastroenterology, Université de Lorraine, Vandoeuvre-les-Nancy, France, **8** AbbVie, Rungis, France

* fanny.depont@sc-partners.eu



OPEN ACCESS

Citation: Depont F, Berenbaum F, Filippi J, Le Maitre M, Nataf H, Paul C, et al. (2015) Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. PLoS ONE 10(12): e0145076. doi:10.1371/journal.pone.0145076

Editor: Xu-jie Zhou, Renal Division, Peking University First Hospital, CHINA

Received: August 10, 2015

Accepted: November 26, 2015

Published: December 16, 2015

Copyright: © 2015 Depont et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: Financial support was provided by AbbVie to SC Partners, a commercial company, for the selection of publications and data analysis, and to FB, JF, MLM, HN, CP and LBP for their participation to scientific boards. The design and study conduct were approved by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. The specific roles of authors are articulated in the "author contributions" section. This

Abstract

Background

In patients with immune-mediated inflammatory disorders, poor adherence to medication is associated with increased healthcare costs, decreased patient satisfaction, reduced quality of life and unfavorable treatment outcomes.

Objective

To determine the impact of different interventions on medication adherence in patients with immune-mediated inflammatory disorders.

Design

Systematic review.

Data sources

MEDLINE, EMBASE and Cochrane Library.

Study eligibility criteria for selecting studies

Included studies were clinical trials and observational studies in adult outpatients treated for psoriasis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis or multiple sclerosis.

financial support had no impact on the selection of publications, data analysis or the publication process.

Competing Interests: FB, JF, MLM, HN, CP and LBP served as consultants to AbbVie and received research funding from AbbVie. ET is an employee of AbbVie and owns AbbVie stock. FD is an employee of SC Partners, a commercial company that received consultancy fees from Abbvie. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. The design and study conduct were approved by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

Study appraisal and synthesis methods

Intervention approaches were classified into four categories: educational, behavioral, cognitive behavioral, and multicomponent interventions. The risk of bias/study limitations of each study was assessed using the GRADE system.

Results

Fifteen studies (14 clinical trials and one observational study) met eligibility criteria and enrolled a total of 1958 patients. Forty percent of the studies (6/15) was conducted in patients with inflammatory bowel disease, half (7/15) in rheumatoid arthritis patients, one in psoriasis patients and one in multiple sclerosis patients. Seven out of 15 interventions were classified as multicomponent, four as educational, two as behavioral and two as cognitive behavioral. Nine studies, of which five were multicomponent interventions, had no serious limitations according to GRADE criteria. Nine out of 15 interventions showed an improvement of adherence: three multicomponent interventions in inflammatory bowel disease; one intervention of each category in rheumatoid arthritis; one multicomponent in psoriasis and one multicomponent in multiple sclerosis.

Conclusion

The assessment of interventions designed for increasing medication adherence in IMID is rare in the literature and their methodological quality may be improved in upcoming studies. Nonetheless, multicomponent interventions showed the strongest evidence for promoting adherence in patients with IMID.

Introduction

Immune-mediated inflammatory disorders (IMIDs) refer to a group of chronic diseases involving an immune response that is inappropriate or excessive, and is caused, signified, or accompanied by dysregulation of the body's normal cytokine milieu [1]. IMIDs bring together conditions such as inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), psoriasis (PS), multiple sclerosis (MS) and rheumatologic conditions (RC) including rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA).

In chronic diseases such as asthma, diabetes or hypertension, up to 30% of physician prescriptions are never filled and about 50% of medications are not taken as prescribed in chronic diseases [2–4]. Similarly, poor adherence to medication is a challenge in clinical practice in patients with IMID [5–7]. In such patients, poor adherence was associated with increased healthcare costs [7], decreased patient satisfaction, reduced quality of life and poor treatment outcomes [5, 8, 9]. These data illustrate the need for efficient interventions to improve medication adherence in IMID patients.

Several intervention studies have been conducted to improve adherence to treatment in IMID patients, including information about disease [10], medication reminders using pill-box or mobile phone [11] and motivational interview [8]. However, there was a high level of heterogeneity in study methods as well as little consistency in their conclusions [12–15], which does not allow to draw clear conclusions about the interventions aimed to improve medication adherence in these conditions.

Table 1. Study inclusion and exclusion criteria.

Category	Inclusion criteria	Exclusion criteria
Population	Adults of 19 years and over, treated with systemic medications for one of the conditions of interest	- Children younger than 18 years (no adult in the study or outcome of interest not stratified by child/adult) - Patients administered medications at hospital - Patients taking over-the counter medications not prescribed by a physician
Conditions of interest	Psoriasis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, multiple sclerosis	- All other conditions
Geographic area	Europe and United States	All other countries
Period	From January 1990 to December 2013	Before 1990
Length of follow-up	No limit	-
Settings	Outpatient care setting	Institutional settings (e.g. Inpatient care, nursing home, prisons)
Interventions	Any intervention intended to improve adherence with prescribed medications	- Interventions intended to improve primary prevention measures (e.g. diet, physical exercise, lifestyle changes) - Intervention assessing change in taking medications (e.g. taken once daily versus twice daily) - Policy intervention (e.g. effect of a health policy on adherence)
Outcomes of interest	- Primary outcome: adherence to medication - Secondary outcomes: Clinical efficacy criteria (e.g. disease activity), quality of life, costs	
Publication language	English	All other language
Type of study	- Original research including clinical trials, observational studies with or without statistically significant improvement in medication adherence - Additional relevant studies manually identified in systematic review	- Case series, case reports, non systematic review, editorials, letters to the editor. - Number of included subject < 30 - Articles rated high risk of bias (very serious limitations)

doi:10.1371/journal.pone.0145076.t001

Using a standardized evaluation process, this systematic review aimed to identify the most suitable interventions to improve medication adherence in patients with IMID, according to the four categories proposed by Greenley et al. [16].

Methods

This systematic review was conducted according to the recommendations presented in the PRISMA Statement [17]. Assistance from clinical experts in dermatology, gastroenterology, and rheumatology was obtained at all stages of protocol generation and implementation. No institutional review board approval was requested because there was no direct involvement of patients. Study protocol is available upon request.

Study selection, eligibility criteria

Interventions intended to improve adherence with prescribed medications in adult outpatients treated for CD, UC, PS, RA, SpA, PsA, MS were assessed (Table 1).

Data sources and searches

To identify relevant articles, targeted literature searches were conducted in MEDLINE, EMBASE and Cochrane Library from January 1990 to December 2013. For each condition of

Table 2. Medline search strategy.

MeSH terms	
1.	"interventions studies" OR "disease management" OR "self care" OR "physician-patient relations*" OR "text messaging"
2.	"patient compliance" OR "medication adherence"
3.	"colitis, ulcerative" OR "crohn disease"
4.	"arthritis, rheumatoid" OR "spondylitis, ankylosing" OR "arthritis, psoriatic"
5.	-
6.	"multiple sclerosis"
Text terms [All Fields]	
1.	"intervention(s)" OR "patient support program" OR "internet" OR "cellular phone" OR "mobile phone" OR "behavioral change techniques" OR "motivational interviewing" OR "psychological support" OR "personalized intervention" OR "personalization"
2.	"compliance" OR "adherence" OR "persistence" OR "consistency"
3.	"crohn" OR "crohn disease" OR "inflammatory bowel disease"
4.	"rheumatoid arthritis" OR "ankylosing spondylitis" OR "psoriatic arthritis"
5.	"psoriasis"
6.	"multiple sclerosis"
Search strategy	
1.	1 AND 2 AND 3
2.	1 AND 2 AND 4
3.	1 AND 2 AND 5
4.	1 AND 2 AND 6

doi:10.1371/journal.pone.0145076.t002

interest, Medical Subject Headings (MeSH) and text terms related to adherence and interventions were identified. Details on the MEDLINE search strategy are presented in [Table 2](#).

The grey literature was reviewed post-hoc (opengrey.eu and greylit.org) but no references related to the subject was found. We also searched relevant citations manually in the reference list of pertinent reviews.

Two trained reviewers screened independently each title and abstracts (FD and SR). All titles selected by at least one reviewer went on full-text review. Conflicts were resolved by discussion and consensus. Clinical experts also reviewed the search strategy.

Data extraction and quality assessment

A trained reviewer extracted data of interest from each study that met the inclusion criteria and summarized them in a structured table. The summarized studies were checked for completeness and accuracy by a second reviewer.

To estimate the magnitude of adherence (size of intervention effect), we calculated the relative risk (RR), which is the ratio of the proportion of patients improving in the intervention group divided by the proportion of patients improving in the control group. RR is easy to interpret and consistent with the way clinicians generally think. [18].

One reviewer (FD) assessed the risk of bias/study limitations of each study using the GRADE system [19]. The five following criteria were examined for clinical trials: 1) Lack of allocation concealment; 2) Lack of blinding; 3) Incomplete accounting of patients and outcome events; 4) Selective outcome reporting bias; 5) Other limitations such as use of non-validated measures of adherence. The risk of bias was quoted: (i) "no serious limitations" if there was a low risk of bias for all these key criteria; (ii) "serious limitations" if there was crucial limitation for one criterion or some limitations for multiple criteria sufficient to lower the confidence in

the estimate of effect; (iii) “*very serious limitations*”. Studies with a very serious limitation quotation were excluded from the review.

Post-hoc study power was calculated from the available data presented in the publication with an online tool [20].

Data analysis—Classification of interventions

A qualitative analysis of extracted data was performed. Intervention approaches were classified into four categories: educational, behavioral, cognitive behavioral, and multicomponent intervention according to Greenley et al [16].

Educational interventions aim to enhance patient knowledge of disease and symptoms, the benefits and mechanisms of action of the medication regimen, the consequences of non-adherence and potential side effects of treatment (example: individual or group educational sessions),

Behavioral interventions promote the act of medication taking and/or reinforce adherence by providing incentives for medication taking (example: text message sending, motivational interview),

Cognitive behavioral interventions enhance adherence by altering thinking patterns that contribute to non-adherence while also establishing behavioral patterns that support adherence using aforementioned behavioral strategies (example: problem-solving skills training),

Multicomponent interventions use multiple strategies to enhance adherence including educational, behavioral, cognitive behavioral, motivational and/or support provision strategies.

Results

Selected studies

Of the 1538 citations identified, 22 published articles met the inclusion criteria at the title and abstract review and 15 articles were finally included after full text review (Fig 1). No publication was found in the Cochrane Library or in the reference list of pertinent reviews. All but one studies were randomized controlled trials (RCTs) and one was an observational study. A total of 1958 patients was enrolled in all included studies, 899 with IBD, 579 with RA, 435 with multiple sclerosis, 40 with psoriasis and 0 with SpA. The intervention duration varied from 3 to 18 months.

Forty percent of the studies (6/15) was conducted in patients with IBD [8, 11, 13, 14, 21, 22], half (7/15) in RA patients [10, 12, 15, 23–26], one in psoriasis patients [27] and one in MS patients [28].

Half the interventions (7/15) were classified as multicomponent interventions [8, 11–13, 21, 27, 28], two as behavioral interventions [15, 24], four as educational interventions [10, 22, 23, 26] and two as cognitive behavioral intervention [14, 25].

Considering the data quality, 9 out of 15 studies had no serious limitations on the basis of the GRADE criteria [11–13, 22, 24–28] whereas 6 had serious limitations, mainly because of lack of power [8, 10, 14, 15, 21, 23]. No study was classified as having « very serious limitations » (Tables 3 and 4).

Measure of medication adherence

Adherence was measured on the basis of the declaratives of patients in 8 studies [8, 12, 13, 22, 24, 25, 27, 28]. The others studies (7/15) used a method for which the reliability was tested [10, 11, 14, 15, 21, 23, 26]. This was either a specific validated questionnaire to measure adherence: Morisky Medication Adherence Score or Compliance Questionnaire on Rheumatology [15, 21]




Fig 1. Study selection flow chart.

doi:10.1371/journal.pone.0145076.g001

or a measure based on data independent from the patient: concentration of medication or metabolites [11, 26], refill data from pharmacies or pill count [10, 14, 23].

Effect of interventions on medication adherence

Among the studies with no serious limitations, 8 out of 9 studies showed an improvement of adherence [11–13, 24–28], versus 1 out of 6 among the studies with serious limitations [8]. The effective interventions with no serious limitations were conducted in all conditions of interest and were mainly multicomponent interventions with patient education [11–13, 27, 28]. The

Table 3. Summary of evidence in studies with no serious limitations.

Condition	Author	Study design	Type of intervention	Adherence assessment / Magnitude of effect (RR)	Post-hoc study power	Risk of bias *
Ulcerative colitis	Elkjaer, 2010	RCT, 12 months	Multicomponent (educational + behavioral) vs. standard care	- Patient report: Adherence to 4 weeks of treatment was increased by 31% in DK and 44% in Ireland (RR = 1.9 DK; 2.5 Ireland)	* DK: 100%	No serious limitations (not validated questionnaire for adherence)
		333 patients		- No effect from prescription database	∅ Ireland: 99%	
	Moshkovska, 2011	RCT, 12 months	Multicomponent (educational + cognitive behavioral) vs. standard care	- Adherence measured with urinary treatment concentration was greater in the intervention group (RR = 2.4)	* 97%	No serious limitations
		71 patients				
IBD	Waters, 2005	RCT, 3 months	Educational vs. standard care	- No significant effect on adherence measured by the mean number of missed medications per month: (difference between groups = 2.52)	∅ 93%	No serious limitations
		89 patients				
Psoriasis	Balato, 2013	RCT, 3 months (pilot study)	Multicomponent (educational + behavioral) vs. standard care	- Adherence to treatment increased in 2.6 days per week in the intervention group whereas no significant variation in the control group in term of days per week in the last week.	* No figure to calculate	No serious limitations
		40 patients				
Rheumatoid arthritis	Hill, 2001	RCT, 6 months	Educational vs. standard care	- Adherence was measured by pharmacological marker	83%	No serious limitations
		100 patients		- At 6 months, 85% of the IG compared with 55% of the CG were taking their medication as prescribed (RR = 1.5)	*	
	Evers, 2002	RCT, 12 months	Cognitive behavioral vs. standard care	- At 12 months, compliance significantly increased in the intervention group (+0.26 on a 3-point scale) while it tended to decrease in the control group	* 40%	No serious limitations
		59 patients				
EI Miedany, 2012a	Pilot RCT, 12 months	111 patients	Behavioral (visualization of disease progression) vs. standard care	- 93% of patients were adherent in the intervention group vs. 70% in the control group (p< 0.01); RR = 1.3	* 89%	No serious limitations
EI Miedany, 2012b	RCT, 18 months	147 patients	Multicomponent (educational + behavioral) vs. standard care	- 89% of patients were adherent in the intervention group vs. 64% in the control group (p< 0.01); RR = 1.4	* 96%	No serious limitations
Multiple sclerosis	Berger, 2005	RCT, 3 months	Multicomponent (educational + behavioral) vs. standard care	-1.2% of patients stopped their medication at 3 months vs. 8.7% in the control group (p< 0.001), RR for adherence = 1.1	* 95%	No serious limitations

(Continued)

Table 3. (Continued)

Condition	Author	Study design	Type of intervention	Adherence assessment / Magnitude of effect (RR)	Post-hoc study power	Risk of bias *
		435 patients				

* According to the GRADE system [19]

*: significant improvement in the intervention group (IG) vs comparator group (CG)

*: significant decrease

∅: no significant difference

BMQ: Beliefs about Medication Questionnaire; BSA: Body Surface Area; CCKNOW: Crohn's and Colitis Knowledge Questionnaire; CQR: Compliance Questionnaire on Rheumatology; DK: Denmark; HAQ-DI: Health Assessment Questionnaire Disability Index; IBD: Inflammatory Bowel Disease; s-IBDQ: Short IBD questionnaire KQ: Knowledge Questionnaire; N/A: Non applicable; PASI: Psoriasis Area Severity Index; PGA: Physician Global Assessment; QoL: Quality of Life; RCT: Randomized clinical trial; RFIPC: Rating Form for IBD Patient Concerns; RR: Relative Risk; SAPASI: Self-administered Psoriasis Area Severity Index; SCCAI: Simple Clinical Colitis Activity Index; SIBDQ: Short Inflammatory Bowel Disease Questionnaire; SIMS: Satisfaction with Information about Medicines Scale.

doi:10.1371/journal.pone.0145076.t003

magnitude of effect as estimated by the RR calculation was moderate ranging from 1.1 to 2.5 in studies with no serious limitations (Table 3).

Among the 6 studies in IBD patients, 3 interventions showed a significant effect on adherence and they were all multicomponent interventions [8, 11, 13]. The 3 other studies in IBD patients had no effect on adherence and represented 3 categories of interventions: educational [22], cognitive behavioral [14], multicomponent [21] (Table 5). Nevertheless, among those 3 studies, two had a very low post-hoc power (Moss et al. and Cross et al. with 37% and 36% respectively), which did not allow to conclude about the effectiveness of these interventions.

In RA, 4 out of 7 interventions showed a significant effect on adherence. These 4 effective interventions corresponded to the 4 different categories of interventions (multicomponent [12], behavioral [24], cognitive behavioral [25] and educational [26]). The 3 others interventions showed negative results. They were two educational interventions [10, 23] and one behavioral intervention [15]. However, these three studies had a dramatic lack of post-hoc power (56%, 17% and 10% respectively).

In psoriasis, the only study included was a multicomponent intervention showed a significant effect on adherence [27]. It was the same thing in multiple sclerosis, with only one multicomponent intervention that showed benefit results on adherence [28].

Discussion

This systematic review was designed to identify the interventions aimed to improve medication adherence in patients with IMID and to evaluate their effectiveness. Fifteen publications met our eligibility criteria. Whereas the timeframe for study selection was 1990–2013, only five studies were identified before 2010 [22, 23, 25, 26, 28]. This small number illustrates the limited attention to adherence, which is a recent concept in IMID.

Our results support medication adherence interventions as tools to enhance adherence. Nine out of 15 interventions showed an improvement of adherence: three multicomponent interventions in inflammatory bowel disease; one intervention of each category in rheumatoid arthritis; one multicomponent in psoriasis and one multicomponent in multiple sclerosis. We found the strongest evidence for multicomponent interventions (i.e. multiple strategies to enhance adherence) in all conditions of interest. These results are consistent with previous

Table 4. Summary of evidence in studies with serious limitations.

Condition	Author	Study design	Type of intervention	Adherence assessment / Magnitude of effect (RR)	Post-hoc study power	Risk of bias *	
Ulcerative colitis	Cook, 2010	Feasibility trial, 6 months	Multicomponent (educational + cognitive behavioral) vs. literature data	- Patient report of adherence (defined as months of treatment completed)	*	80%	Serious limitations (no randomization, no control group, high attrition rate of 51%)
		278 patients		- Participants had higher adherence up to 6 months than the expected rate (RR: 1.5)			
	Cross, 2012	RCT, 12 months	Multicomponent (home telemanagement system educational + behavioral) vs. standard care	- Adherence measure: MMAS-4		36%	Serious limitations (lack of power due to insufficient recruitment)
		47 patients		- At 12 months, 44% of patients were adherent in the intervention group vs. 68% in the control group (p = 0.10)			
Rheumatoid arthritis	Moss, 2010	RCT, 6 months	Cognitive behavioral vs. standard care	- By 6 months, percentage of adherent patients, based on refill data from pharmacies, increased to 67% in the control group vs 50% in the intervention group (p = 0.3)	∅	37%	Serious limitations (lack of power due to effect size lower than expected)
		81 patients					
	Van den Bemt, 2011	Mirror image (before-after) study, 6 months	Behavioral (report on patient adherence hand to physician) vs. standard care	- Adherence measure: CQR		≤ 10%	Serious limitations (lack of power)
		50 patients		- No change in adherence after intervention compared to prior intervention (p = 0.68)			
Rheumatoid arthritis	Homer, 2009	Pilot RCT, 12 months	Educational individual vs. group counseling	- Pill count: 90% patients counseled in group were adherent vs. 69% patients counseled individually (p = 0.06)	∅	56%	Serious limitations (lack of power)
		62 patients		- On self-reported diaries proportions were similar: group counseling: 97% vs. individual: 94% (p = 1.0)			
	Brus, 1998	RCT, 12 months	Educational Experimental group (6 education meeting) vs control group (Brochure on RA)	- After one year, 60% of the patients in the experimental group and 76% in the control group were still using sulphasalazine (p<0.05)	∅	17%	Serious limitations (lack of power)
		55 patients					

* According to the GRADE system [19]

*: significant improvement in the intervention group (IG) vs comparator group (CG)

∅: no significant difference

BMQ: Beliefs about Medication Questionnaire; CQR: Compliance Questionnaire on Rheumatology; HAQ-DI: Health Assessment Questionnaire Disability Index; MMAS-4: Morisky Medication Adherence Score. QoL: Quality of Life; RCT: Randomized clinical trial; RR: Relative Risk; SCAI: Simple Colitis Activity index; SIBDQ: Short Inflammatory Bowel Disease Questionnaire; SIMS: Satisfaction with Information about Medicines Scale.

doi:10.1371/journal.pone.0145076.t004

reviews in other chronic conditions such as hypertension, hyperlipidemia, asthma, diabetes or heart failure [29–31]. A meta-analysis of intervention studies on medication adherence published between 1977 and 1994, showed that multidimensional approaches were more effective than unidimensional interventions [30].

Heterogeneity of the published studies did not permit to perform a meta-analysis. In addition, the limited number of studies for psoriasis and multiple sclerosis, for which only one study was identified, needs to be underlined. There is a need to strengthen the evidence regarding the ability of interventions to improve adherence in IMID with well controlled studies.

Despite these limitations, the group of intervention studies identified in this review constitutes a first skeleton from which clinicians and researchers can develop further studies by taking into account the strengths and weaknesses we observed. One major point of improvement should be the quality of study design, especially *a priori* sample size determination to ensure sufficient power to detect a clinically relevant effect. It is noteworthy that 6 out of 15 studies had a dramatic lack of power (<60%). Increasing the power of studies would avoid false negative results, which probably was the case for some of them.

Another point of progress relates to the measure of adherence. Indeed, we observed that a large number of studies (8 out of 15) did not use standardized and validated instruments and are only based on the declaratives of patients. This prevents from comparison between studies and hampers the conduct of meta-analyses. Nonetheless, validated scales exist such as the Morisky Medication Adherence Scale (MMAS, also known as Medication Adherence Questionnaire), which is the first published and the most commonly used adherence scale. [32, 33]. Though there is no gold standard scale for measuring adherence to medication, MMAS is very often recommended because it has a good reliability, is the quick to administer and score and has been validated in the broadest range of diseases [34, 35]. Refill data from pharmacy administrative databases can also be useful for measuring medication adherence, but the analysis of such data need trained researchers to correctly defined and interpreted the adherence indicators [36].

Future research should also attempt to clearly describe all the components of the intervention and to try to identify which specific component is necessary to enhance adherence. Some components may have additive effects, other may have synergistic effects.

Table 5. Effectiveness of intervention according to the type of intervention and study limitations.

	Educational n = 4	Behavioral n = 2	Cognitivo-behavioral n = 2	Multicomponent n = 7
Studies with no serious limitations				
IBD n = 3	∅	-	-	++
Rheumatoid arthritis n = 4	+	+	+	+
Psoriasis n = 1	-	-	-	+
Multiple sclerosis n = 1	-	-	-	+
Effectiveness*	1/2	1/1	1/1	5/5
Studies with serious limitations				
IBD n = 3	-	-	∅	+ ∅
Rheumatoid arthritis n = 3	∅ ∅	∅	-	-
Effectiveness*	0/2	0/1	0/1	1/2
TOTAL EFFECTIVENESS	1/4	1/2	1/2	6/7

∅: negative study

+: positive study (i.e. effective intervention)

*Effectiveness: number of effective studies out of the total number of studies.

doi:10.1371/journal.pone.0145076.t005

The few number of studies identified in this systematic review did not allow to propose recommendations to improve adherence for clinical practice. Nevertheless, our results support the guidelines developed by the National Institute for Health and Clinical Excellence (NICE) regarding medicines adherence and the involvement of patients in decisions about prescribed medicines and supporting adherence [37]. These guidelines indicate that patients need support to improve their medicine taking. This support may take the form of: (i) further information and discussion about the patient beliefs, their concerns and their practical problems about the medicines, and (ii) encouragements to record their medicine taking, to use alternative packaging or a multi-compartment medication device. Because the evidence supporting interventions to increase adherence was inconclusive, the NICE guidelines recommend to consider any intervention to improve adherence on a case by case basis and to tailor the intervention to the specific need of the patient. The recommendations also include advice to healthcare professionals to strengthen communication between the many professionals who may be involved in the individual patient care.

In conclusion, few studies are currently available that evaluate interventions aiming to improve medication adherence in IMID. Although some of them are well-designed, the overall quality of studies could be improved. This regards particularly *a priori* sample size estimation and selection of validated instruments to measure adherence. Nonetheless, the results from this systematic review show that multicomponent interventions appear to be the most efficient in improving adherence to medication.

Supporting Information

S1 PRISMA Checklist.

(DOC)

Acknowledgments

The authors thank Assia Mouglaam and Sandrine Rosso for their participation to the selection of publications.

Author Contributions

Conceived and designed the experiments: FD FB JF MLM HN CP LBP ET. Performed the experiments: FD. Analyzed the data: FD FB JF MLM HN CP LBP ET. Wrote the paper: FD FB JF MLM HN CP LBP ET.

References

1. Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. *Am J Manag Care*. 2002; 8(21 Suppl):S664–81; quiz S82-5. Epub 2003/01/09. 144 [pii]. PMID: [12516953](#).
2. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. *Int J Clin Pract*. 2008; 62(1):76–87. Epub 2007/11/07. *IJCP*1630 [pii] doi: [10.1111/j.1742-1241.2007.01630.x](#) PMID: [17983433](#).
3. Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. *Respir Med*. 2013; 107(10):1481–90. Epub 2013/05/07. S0954-6111(13)00134-0 [pii] doi: [10.1016/j.rmed.2013.04.005](#) PMID: [23643487](#).
4. World Health Organization. Adherence to long-term therapies: evidence for action Geneva. 2003. Available: http://www.who.int/chp/knowledge/publications/adherence_report/en/.
5. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. *Dermatology*. 2011; 222(4):363–74. Epub 2011/07/16. 000329026 [pii] doi: [10.1159/000329026](#) PMID: [21757881](#).

6. Hill J. Adherence with drug therapy in the rheumatic diseases Part one: a review of adherence rates. *Musculoskeletal Care*. 2005; 3(2):61–73. Epub 2006/10/17. doi: [10.1002/msc.27](https://doi.org/10.1002/msc.27) PMID: [17041995](https://pubmed.ncbi.nlm.nih.gov/17041995/).
7. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. *Dig Dis Sci*. 2008; 53(4):1020–4. Epub 2007/10/16. doi: [10.1007/s10620-007-9968-0](https://doi.org/10.1007/s10620-007-9968-0) PMID: [17934828](https://pubmed.ncbi.nlm.nih.gov/17934828/).
8. Cook PF, Emiliozzi S, El-Hajj D, McCabe MM. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. *Patient Educ Couns*. 2010; 81(2):182–6. Epub 2010/01/19. S0738-3991(09)00609-0 [pii] doi: [10.1016/j.pec.2009.12.010](https://doi.org/10.1016/j.pec.2009.12.010) PMID: [20079598](https://pubmed.ncbi.nlm.nih.gov/20079598/).
9. Thorneloe RJ, Bundy C, Griffiths C, Ashcroft D, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. *British Journal of Dermatology*. 2012; 168:20–31.
10. Homer D, Nightingale P, Jobanputra P. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. *Musculoskeletal Care*. 2009; 7(2):78–92. Epub 2008/09/16. doi: [10.1002/msc.141](https://doi.org/10.1002/msc.141) PMID: [18792423](https://pubmed.ncbi.nlm.nih.gov/18792423/).
11. Moshkovska T, Stone MA, Smith RM, Bankart J, Baker R, Mayberry JF. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. *Inflamm Bowel Dis*. 2011; 17(9):1874–81. Epub 2011/08/11. doi: [10.1002/ibd.21570](https://doi.org/10.1002/ibd.21570) PMID: [21830265](https://pubmed.ncbi.nlm.nih.gov/21830265/).
12. El Miedany Y, El Gaafary M, El Arousy N, Ahmed I, Youssef S, Palmer D. Arthritis education: the integration of patient-reported outcome measures and patient self-management. *Clin Exp Rheumatol*. 2012b; 30(6):899–904. Epub 2012/09/21. 5564 [pii]. PMID: [22992291](https://pubmed.ncbi.nlm.nih.gov/22992291/).
13. Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. *Gut*. 2010; 59(12):1652–61. Epub 2010/11/13. 59/12/1652 [pii] doi: [10.1136/gut.2010.220160](https://doi.org/10.1136/gut.2010.220160) PMID: [21071584](https://pubmed.ncbi.nlm.nih.gov/21071584/).
14. Moss AC, Chaudhary N, Tukey M, Junior J, Cury D, Falchuk KR, et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis—a prospective study. *J Crohns Colitis*. 2010; 4(2):171–5. Epub 2010/12/03. S1873-9946(09)00107-X [pii] doi: [10.1016/j.crohns.2009.10.002](https://doi.org/10.1016/j.crohns.2009.10.002) PMID: [21122501](https://pubmed.ncbi.nlm.nih.gov/21122501/).
15. van den Bemt BJ, den Broeder AA, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, et al. Making the rheumatologist aware of patients' non-adherence does not improve medication adherence in patients with rheumatoid arthritis. *Scand J Rheumatol*. 2011; 40(3):192–6. Epub 2010/10/28. doi: [10.3109/03009742.2010.517214](https://doi.org/10.3109/03009742.2010.517214) PMID: [20977385](https://pubmed.ncbi.nlm.nih.gov/20977385/).
16. Greenley RN, Kunz JH, Walter J, Hommel KA. Practical strategies for enhancing adherence to treatment regimen in inflammatory bowel disease. *Inflamm Bowel Dis*. 2013; 19(7):1534–45. Epub 2013/05/03. doi: [10.1097/MIB.0b013e3182813482](https://doi.org/10.1097/MIB.0b013e3182813482) PMID: [23635715](https://pubmed.ncbi.nlm.nih.gov/23635715/).
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med*. 2009; 6(7):e1000100. Epub 2009/07/22. doi: [10.1371/journal.pmed.1000100](https://doi.org/10.1371/journal.pmed.1000100) PMID: [19621070](https://pubmed.ncbi.nlm.nih.gov/19621070/).
18. McGough JJ, Faraone SV. Estimating the size of treatment effects: moving beyond p values. *Psychiatry (Edgmont)*. 2009; 6(10):21–9. Epub 2009/12/17. PMID: [20011465](https://pubmed.ncbi.nlm.nih.gov/20011465/).
19. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). *J Clin Epidemiol*. 2011; 64(4):407–15. Epub 2011/01/21. S0895-4356(10)00413-0 [pii] doi: [10.1016/j.jclinepi.2010.07.017](https://doi.org/10.1016/j.jclinepi.2010.07.017) PMID: [21247734](https://pubmed.ncbi.nlm.nih.gov/21247734/).
20. Anstats. Téléchargements d'utilitaires et d'exercices 2014. Available: <http://www.anstats.fr/stats/Telechargement.htm#puissance>. Accessed: 2014 February 27.
21. Cross RK, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). *Inflamm Bowel Dis*. 2012; 18(6):1018–25. Epub 2011/06/21. doi: [10.1002/ibd.21795](https://doi.org/10.1002/ibd.21795) PMID: [21688350](https://pubmed.ncbi.nlm.nih.gov/21688350/).
22. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. *Can J Gastroenterol*. 2005; 19(4):235–44. Epub 2005/04/30. PMID: [15861266](https://pubmed.ncbi.nlm.nih.gov/15861266/).
23. Brus HL, van de Laar MA, Taal E, Rasker JJ, Wiegman O. Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. *Ann Rheum Dis*. 1998; 57(3):146–51. Epub 1998/06/26. PMID: [9640129](https://pubmed.ncbi.nlm.nih.gov/9640129/).
24. El Miedany Y, El Gaafary M, Palmer D. Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study. *Rheumatol Int*. 2012a; 32(10):3061–8. Epub 2011/09/13. doi: [10.1007/s00296-011-2098-1](https://doi.org/10.1007/s00296-011-2098-1) PMID: [21909946](https://pubmed.ncbi.nlm.nih.gov/21909946/).

25. Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ. Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. *Pain*. 2002; 100(1–2):141–53. Epub 2002/11/19. S0304395902002749 [pii]. PMID: [12435467](#).
26. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. *Ann Rheum Dis*. 2001; 60(9):869–75. Epub 2001/08/15. PMID: [11502614](#).
27. Balato N, Megna M, Di Costanzo L, Balato A, Ayala F. Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis. *Br J Dermatol*. 2013; 168(1):201–5. Epub 2012/12/18. doi: [10.1111/j.1365-2133.2012.11205.x](#) PMID: [23240729](#).
28. Berger BA, Liang H, Hudmon KS. Evaluation of software-based telephone counseling to enhance medication persistency among patients with multiple sclerosis. *J Am Pharm Assoc (2003)*. 2005; 45(4):466–72. Epub 2005/09/01. PMID: [16128502](#).
29. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2008;(2):CD000011. Epub 2008/04/22. doi: [10.1002/14651858.CD000011.pub3](#) PMID: [18425859](#).
30. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. *Med Care*. 1998; 36(8):1138–61. Epub 1998/08/26. PMID: [9708588](#).
31. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. *Ann Intern Med*. 2012; 157(11):785–95. Epub 2012/09/12. 1357338 [pii] doi: [10.7326/0003-4819-157-11-201212040-00538](#) PMID: [22964778](#).
32. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. *J Clin Hypertens (Greenwich)*. 2008; 10(5):348–54. Epub 2008/05/06. PMID: [18453793](#).
33. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care*. 1986; 24(1):67–74. Epub 1986/01/01. PMID: [3945130](#).
34. Culig J, Leppée M. From Morisky to Hill-bone; self-reports scales for measuring adherence to medication. *Coll Antropol*. 2014; 38(1):55–62. Epub 2014/05/24. PMID: [24851597](#).
35. Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. *J Am Pharm Assoc (2003)*. 2011; 51(1):90–4. Epub 2011/01/21. DQL11H6140625136 [pii] doi: [10.1331/JAPhA.2011.09154](#) PMID: [21247831](#).
36. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. *Ann Pharmacother*. 2006; 40(7–8):1280–88. Epub 2006/07/27. aph.1H018 [pii] doi: [10.1345/aph.1H018](#) PMID: [16868217](#).
37. National Collaborating Centre for Primary Care, National Institute for Health and Clinical Excellence. *Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence*. London 2009.